Valye reports for unlimited access

K2 Capital Acquisition Corp is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands with the purpose of effecting an initial business combination through merger, share exchange, asset acquisition, share purchase, reorganization, or similar transaction. The company completed its initial public offering in January 2026, raising gross proceeds of $138 million, which are held in a trust account for the benefit of public shareholders. The company has not yet selected a business combination target and has not initiated substantive discussions with any potential targets. The management team intends to focus on opportunities in the emerging Physical AI sector, which combines robotics, AI, sensor fusion, and biomechanical engineering, as well as in the advanced energy sector, particularly small modular nuclear reactors (SMRs). The company’s acquisition strategy targets technology companies primarily in northern Europe with enterprise valuations between $150 million and $750 million. The company currently has no operations and limited liquidity, with a current ratio below 1 as of the latest fiscal year end. It has up to 18 months from its IPO to complete a business combination, subject to possible extensions with shareholder approval.

22nd Century Group, Inc. is a tobacco company dedicated to tobacco harm reduction through the development and commercialization of reduced nicotine content combustible cigarettes. The company’s mission is to provide adult smokers with cigarette alternatives that significantly reduce nicotine exposure, potentially reducing dependence while preserving consumer choice. It operates two leased tobacco facilities in North Carolina, which serve as manufacturing and storage sites as well as its headquarters. The company’s product portfolio includes proprietary VLN® reduced nicotine cigarettes and contract manufacturing of cigarettes, filtered cigars, and other tobacco products. It has established partnerships with national convenience store chains and independent retailers such as Smoker Friendly to distribute its products across multiple states. The company exited its hemp/cannabis business in late 2023 and now operates a single tobacco segment. Financially, 22nd Century Group reported net revenues of $17.59 million for 2025, a decline from the prior year, with a gross loss and operating loss reflecting ongoing challenges in product mix and market conditions. The company has strengthened its balance sheet by eliminating debt and improving liquidity, holding over $7 million in cash and equivalents as of year-end 2025. It continues to focus on regulatory alignment, marketing initiatives, and product launches to advance its growth strategy.

Founded in 1965, M-tron Industries, Inc. specializes in designing, manufacturing, and marketing high reliability frequency and spectrum control products used in electronic circuits across aerospace, defense, avionics, industrial, and space sectors. The company’s product portfolio includes quartz crystal resonators, oscillators, RF and microwave filters, power amplifiers, and integrated microwave assemblies. M-tron supports customers throughout product life cycles with engineering services, fostering long-term relationships primarily with OEMs. Manufacturing is conducted in certified facilities in Florida, South Dakota, and India, with a sales office in Hong Kong. The company’s business is concentrated in aerospace and defense (65.2% of 2025 revenues), avionics (22.7%), industrial (8.1%), and space (4.0%). M-tron reported a $76.4 million order backlog as of December 31, 2025, reflecting firm orders expected to be fulfilled mainly within 12 to 24 months. The company invests in research and development to enhance product capabilities and maintain competitive differentiation.

Prudential PLC operates in the life and health insurance and asset management sectors, focusing on markets in Greater China, ASEAN, India, and Africa. The company provides financial and health solutions aimed at being a trusted partner for current and future generations. It is listed on multiple stock exchanges including Hong Kong, London, Singapore, and New York. Prudential PLC reported $11.49 billion in revenue and $4.12 billion in net income for the fiscal year ending December 31, 2025, with cash and cash equivalents of $7.71 billion. The company has engaged in share repurchases in early 2026 and plans to cancel repurchased shares, reducing share count. It is not affiliated with similarly named entities in the US or UK. The company has received analyst coverage including reiterated overweight recommendations from JP Morgan Cazenove and has been featured in comparative value analyses against peers [S1][S2][N1][N6][N7].

AngloGold Ashanti PLC is a multinational gold mining company formed through consolidation and business combinations since 1998, with a corporate restructuring completed in 2023 establishing it as a UK parent company. The company operates mining assets across Africa, the Americas, and Australia, with a focus on gold production and exploration. It maintains listings on the NYSE and other exchanges. The company’s financial position as of the end of 2025 shows strong liquidity and profitability. Key projects include the Arthur Gold Project in Nevada, which has been recently advanced with a significant Mineral Reserve and pre-feasibility study demonstrating competitive costs and a long mine life. The company has actively managed its portfolio through acquisitions and divestitures, including the acquisition of Augusta Gold Corp. and sales of certain mines and projects. AngloGold Ashanti engages in community initiatives and emphasizes environmental stewardship and stakeholder engagement in its operations.

AEGON LTD. is a publicly listed company registered in the Netherlands, operating in the financial sector as inferred from news and filings. It files annual and quarterly reports with the SEC, providing periodic financial disclosures. The company reported significant revenue in 2022 and positive net income in 2025, with liquidity supported by cash, equivalents, and short-term investments. AEGON is undergoing strategic changes including relocating its head office to the US and rebranding as Transamerica, alongside a substantial share buyback program. Market commentary and news coverage focus on its valuation relative to peers and recent stock price trends.

Brookfield Wealth Solutions Ltd. was incorporated in 2020 in Bermuda and focuses on securing financial futures through retirement services, wealth protection products, and tailored capital solutions. Its business is conducted through subsidiaries operating in four segments: Annuities, Property and Casualty insurance, Life Insurance, and Corporate and Other. The company offers a broad range of insurance products including fixed index and fixed rate annuities, pension risk transfer, funding agreements, whole life, universal life, and variable universal life insurance, as well as property, casualty, and specialty insurance products. BNT leverages its strategic relationship with Brookfield Corporation, a global investment firm with over $1 trillion in assets under management, to source new business and deploy capital into alternative investments aligned with its liabilities. The company has completed significant acquisitions such as AEL Holdings and Clearbrook, expanding its product offerings and market presence. It maintains substantial liquidity and access to capital through cash reserves, credit facilities, and equity commitments from Brookfield. BNT faces competition from established insurance companies, financial institutions, and alternative asset managers, with competitive pressures on pricing and product innovation. Regulatory requirements and credit ratings also influence its operations and funding costs [S1].

Innovative Eyewear Inc develops and markets smart eyewear designed to combine traditional eyewear aesthetics with integrated audio and digital assistant capabilities. Founded in 2019 and headquartered in Miami, the company offers a diverse portfolio of 34 models across prescription, sunglasses, safety, and sport categories. Key product lines include Lucyd Lyte, Lucyd Armor safety glasses certified in multiple jurisdictions, and cobranded collections with Nautica, Eddie Bauer, and Reebok. The eyewear supports hands-free voice commands for communication, payments, navigation, and music, enhanced by the Lucyd app which integrates ChatGPT and other voice assistants. Products are designed in the US and manufactured in China, with quality control conducted domestically. Sales channels include direct e-commerce, major online marketplaces, and over 400 retail stores in the US and Canada, with expanding international distribution. The company holds over 120 patents and applications related to its technology. Financially, the company reported $2.66 million in revenue and a net loss of $7.59 million for 2025, maintaining strong liquidity with a current ratio above 9. Recent news highlights include new product launches, strategic partnerships, and capital raises.

Serina Therapeutics develops a proprietary polymer drug delivery platform called POZ, based on poly(2-oxazoline), designed to improve pharmacokinetics and safety profiles of drugs through controlled release and targeted delivery. The company’s lead clinical candidate, SER 252, is a POZ conjugate of apomorphine for advanced Parkinson’s disease, intended to provide continuous dopaminergic stimulation via convenient subcutaneous injections. Serina also explores applications of POZ technology in lipid nanoparticle delivery and antibody-drug conjugates, with partnerships including a non-exclusive license agreement with Pfizer. The company has completed early-stage clinical trials for SER 214 and is advancing SER 252 in Phase 1b trials. Serina is a clinical-stage company with no product revenues and ongoing operating losses, relying on financing and partnerships to fund development.

ECB Bancorp, Inc. operates as a community bank focused on serving customers in and around Everett, Massachusetts. Its core business involves accepting deposits and investing these funds primarily in a diversified portfolio of real estate loans, including one-to-four family residential, multifamily, commercial, construction loans, and home equity lines of credit. The company also invests in various securities such as U.S. government obligations and mortgage-backed securities. Deposits are diversified across certificates of deposit, money market accounts, savings, and demand deposits, supplemented by brokered deposits and Federal Home Loan Bank advances. The company reported net income of $7.8 million for 2025, with earnings per share near $0.96. Its business strategy emphasizes growth in commercial and multifamily real estate lending, prudent underwriting to maintain asset quality, expanding deposit relationships, and branch network expansion. ECB Bancorp also employs interest rate swaps to manage interest rate risk. The company has an active stock repurchase program and a history of insider buying activity.

Global Self Storage, Inc. operates as a real estate investment trust (REIT) focused exclusively on self storage properties across various U.S. markets. The company competes with national, regional, and local operators, emphasizing high-quality operations that prioritize tenant convenience, security, and professionalism. It maintains REIT qualification by distributing most of its taxable income to stockholders and managing its income sources and asset composition accordingly. The company also pursues sustainability initiatives to reduce environmental impact, including solar panel installations and energy-efficient upgrades. Financially, the company reported $12.7 million in revenue and $2.0 million in net income for fiscal year 2025, with a cash balance of $7.4 million at year-end. The business model is subject to risks from economic conditions, competition, regulatory changes, and financing constraints [S1].

NIKA PHARMACEUTICALS, INC. is a pharmaceutical company incorporated in Colorado in 2000. The company has shifted its business focus to production and distribution of pharmaceutical products and dietary supplements through exclusive rights agreements. Key products include Thymus Nuclear Glycoprotein (TNG), which has clinical trial history related to HIV treatment, and dietary supplements Carotilen and Physiolong. NIKA has strategic partnerships and joint business agreements to develop and distribute medicinal products based on patented technologies. The company merged with Nika BioTechnology, Inc. in 2024, consolidating its ownership in Nika Europe, Ltd., which is preparing to build a pharmaceutical manufacturing facility. NIKA’s common stock is listed on OTCQB under the ticker NIKA. Financially, the company reported no revenue for fiscal year 2024 and a net loss for fiscal year 2025, with limited liquidity as of the end of 2025. The company operates with a small executive team and has not yet adopted formal insider trading policies.

PFS Bancorp, Inc. was incorporated in 2023 as the holding company for Peru Federal Savings Bank following its conversion to a stock organization. The company operates primarily in LaSalle County, Illinois, and surrounding areas, focusing on deposit gathering and lending, mainly one- to four-family residential mortgage loans. The loan portfolio also includes commercial real estate, commercial loans, and other loan types. The company is regulated by the Federal Reserve Board, OCC, and FDIC, and offers electronic banking services. It faces competition from various financial institutions in its market area.

KAANAPALI LAND LLC is a Delaware limited liability company focused on land investment and development on Maui, Hawaii. The company operates two main business segments: Property, which involves land sales, development, and leasing; and Agriculture, which includes coffee farming, milling, and related sales. Revenue recognition for property sales occurs at closing, while agricultural and other revenues are recognized upon transfer of goods or services. The company has been impacted by the Lahaina wildfires, resulting in property damage and related insurance claims. Financial statements indicate ongoing net losses and significant expenses related to rebuilding and operations.

Fidelity Solana Fund (the Trust) is an exchange-traded product formed as a Delaware Statutory Trust in March 2025 and commenced operations in November 2025. The Trust issues common shares listed on NYSE Arca, representing fractional undivided beneficial interest in the Trust's holdings of SOL, the native token of the Solana blockchain. The Trust's investment objective is to track the performance of SOL as measured by the Fidelity Solana Reference Rate (the Index), adjusted for expenses and liabilities, plus staking rewards. The Trust holds SOL directly, with all tokens held by qualified Custodians. The Sponsor manages the Trust passively without leverage or derivatives and utilizes staking activities through trusted node operators to generate staking rewards, which are shared with the Trust net of fees. The Trust sells and redeems shares in blocks of 25,000 shares (Baskets) based on the SOL attributable to each share. The Trust provides investors with access to SOL through traditional brokerage accounts without the risks of direct SOL ownership or transfer. The Trust's NAV is calculated daily using the Index price methodology, which is a volume-weighted median price composite from eligible spot markets. The Sponsor charges an annual fee of 0.25% of SOL holdings, with a fee waiver for the first six months after commencement, and the Trust bears a 15% staking fee. The Trust reported a net loss of $6.1 million for the fiscal year ended December 31, 2025.

FVCBankcorp, Inc. operates as a bank holding company with its sole subsidiary, FVCbank, a community-oriented commercial bank headquartered in Fairfax, Virginia. The bank serves small and medium-sized businesses, nonprofit organizations, professionals, and individual customers primarily in the Washington, D.C. and Baltimore metropolitan areas. The company has grown organically and through acquisitions since its inception in 2007. It offers a wide range of banking services including commercial and retail banking, digital and mobile banking, treasury management, insurance, and merchant services. Lending products focus on commercial real estate, commercial construction, government contract financing, SBA loans, home equity loans, and consumer loans. The company manages credit risk through underwriting, portfolio monitoring, and an allowance for credit losses based on peer data and economic forecasts. The company reported net income of $22.06 million and EPS of $1.22 for fiscal 2025 [S1][S2].

Horizon Quantum Holdings Ltd. operates in the emerging quantum computing industry, developing software infrastructure aimed at enabling practical applications of quantum hardware. The company’s business model depends on achieving quantum advantage and establishing strategic collaborations with hardware vendors. Its customer base primarily includes governmental agencies, large enterprises, and research institutions, which typically have longer sales cycles. Horizon Quantum completed a Business Combination with dMY Squared Technology Group, Inc. in March 2026, raising significant capital through SAFEs and a PIPE private placement. The company is headquartered in Singapore and files annual reports on Form 20-F with the SEC as a foreign private issuer [S1][S2].

EWSB Bancorp, Inc. is a Maryland-based public company owning East Wisconsin Savings Bank, a Wisconsin-chartered stock savings bank with headquarters in Kaukauna and branches in Appleton, Freedom, and Kimberly, Wisconsin. The bank's core business involves accepting deposits and originating loans, primarily one- to four-family residential real estate loans, which constitute the majority of its loan portfolio. Other loan types include marine and recreational vehicle loans, construction loans, home equity loans and lines of credit, commercial loans, and other consumer loans. The bank also invests in securities such as U.S. Treasury and federal agency securities and corporate bonds. The company completed its IPO in September 2024, raising approximately $7.5 million. It operates under comprehensive regulation by the Federal Reserve Board, Wisconsin Department of Financial Institutions, and the FDIC. The primary lending market is Outagamie County, Wisconsin, and adjoining counties, an area with a diverse economic base. The company faces competition from a range of financial institutions including large banks, community banks, credit unions, and fintech firms.

Park Dental Partners, Inc. operates as a dental resource organization (DRO) providing business support services such as staffing, facilities, equipment, billing, marketing, and administrative functions to affiliated dental practices. The affiliated practices deliver both general and specialty dental services under long-term agreements, primarily in Minnesota, Wisconsin, and Arizona. The company’s network includes 214 dentists and 990 supporting clinical and administrative personnel across 86 locations. The business model is dentist-majority owned, with affiliated dentists having governance rights and active operational involvement. The company has grown through acquisitions and organic expansion, with revenues of $244.5 million in 2025. The U.S. dental services industry is characterized by fragmentation, consumer-driven payment models, and increasing insurance coverage. Park Dental Partners leverages centralized management and economies of scale to support affiliated practices and enhance patient care and operational efficiency.

Lucid Diagnostics Inc. develops and commercializes diagnostic technology aimed at early detection of esophageal adenocarcinoma (EAC) and its precursors in patients with gastroesophageal reflux disease (GERD). Its flagship product, EsoGuard, is a DNA methylation assay performed on esophageal cells collected non-invasively using the EsoCheck device. EsoGuard and EsoCheck are FDA 510(k)-cleared and CE Mark certified, and are based on patented technology licensed from Case Western Reserve University. The company targets a large U.S. market of approximately 30 million at-risk patients recommended for screening by clinical guidelines. EsoGuard is endorsed by major gastroenterology societies as an alternative to invasive endoscopy for Barrett's Esophagus screening. Lucid commercializes its products through owned and satellite test centers, mobile units, telemedicine, and direct contracting with employers and health systems. It has secured Medicare payment and is actively pursuing expanded coverage. Clinical utility and validity are supported by multiple studies and ongoing NIH- and DOD-funded trials. Manufacturing capacity for EsoCheck is scalable through established partners. Financially, the company reported $1.21 million revenue for Q3 2025 and a net loss of $58.0 million for fiscal 2025, with a strong cash position as of September 2025.

Precigen, Inc. operates in the biotechnology sector, specializing in precision medicine by leveraging synthetic biology technologies to develop gene and cell therapies. The company utilizes proprietary platforms such as UltraVector, AdenoVerse, and UltraCAR-T to design and deliver multigenic gene programs aimed at treating complex diseases. Its clinical pipeline includes lead candidates like Papzimeos, approved for recurrent respiratory papillomatosis (RRP), with regulatory designations and ongoing market access initiatives. Precigen maintains internal manufacturing capabilities and has established commercial supply agreements to support product production. The company manages a senior secured term loan facility to fund operations and development. Its strategy emphasizes financial discipline, active portfolio management, rapid execution, and strategic partnerships to advance its pipeline and commercial products [S1][S17][S20].

SeaStar Medical Holding Corp develops and commercializes the Selective Cytopheretic Device (SCD) therapy, a disease-modifying extracorporeal device that targets activated neutrophils and monocytes to reduce destructive hyperinflammation (cytokine storm) in critically ill patients. The therapy has FDA Humanitarian Device Exemption approval for pediatric acute kidney injury (AKI) patients with sepsis requiring kidney replacement therapy, marketed as QUELIMMUNE. The company is conducting a pivotal clinical trial (NEUTRALIZE-AKI) for adult AKI patients receiving continuous renal replacement therapy (CRRT). The SCD therapy integrates into existing CRRT systems using regional citrate anticoagulation to create a low calcium environment that modulates immune cells without causing immunosuppression. SeaStar holds multiple FDA Breakthrough Device Designations for various adult indications and is expanding clinical development into additional acute and chronic inflammatory conditions. The company uses a direct sales model for pediatric therapy and is developing reimbursement strategies for adult indications. SeaStar faces operational and financial challenges, including recurring losses, the need for additional capital, and regulatory approval risks.

Marpai, Inc. operates as a technology platform company offering healthcare administrative services to self-insured employers in the United States. Its subsidiaries provide Third Party Administrator (TPA) services, Pharmacy Benefit Management (PBM), and value-oriented health plan services. The company primarily serves small and medium-sized enterprises and local government entities. Marpai's core offerings include health plan administration services such as claims adjudication, member support, provider network access, and stop-loss insurance sourcing. Ancillary services include clinical care management, pharmacy savings programs, and repricing of out-of-network claims. The company leverages deep learning and data analytics to improve healthcare outcomes and reduce costs, supported by an in-house clinical team and a mobile app for members. Marpai operates in a highly regulated environment with compliance obligations under federal and state healthcare laws. The market is competitive with many regional and national players. The company reported $18.1 million in revenue and a net loss of $16.6 million for the fiscal year ended December 31, 2025, with liquidity constraints and ongoing strategic reviews.

Dakota Gold Corp. was incorporated in 2017 and focuses on acquiring, exploring, and developing gold mineral properties in the Homestake District of South Dakota, USA. The company owns over 49,500 acres of mineral claims and leases in this historically productive gold district. It operates solely in the mineral exploration and evaluation segment and has not commenced mining or generated revenues. The company leverages extensive management and technical experience, including decades of expertise in the Homestake District, to advance its projects using modern exploration techniques and geophysical surveys. Key projects include the Richmond Hill and Maitland properties, with ongoing drilling programs and permitting activities. The company aims to move projects from exploration to development and production as exploration results dictate [S1][S2][S6].

Exicure, Inc. was historically focused on developing nucleic acid therapies targeting RNA but suspended all R&D activities in 2022 and sold its biotechnology intellectual property in 2024. The company is now focused on exploring strategic alternatives including acquisitions and partnerships, with a notable acquisition of GPCR Therapeutics USA Inc. in 2025. GPCR USA's Phase 2 clinical trial for a CXCR4 inhibitor in Multiple Myeloma completed in early 2026, marking a key milestone. Exicure has no current product revenue and continues to incur operating losses, relying on cash reserves and financing to support operations. The company faces liquidity constraints and Nasdaq listing compliance risks. Significant stockholders hold substantial influence over corporate governance.

CATO CORP is a publicly traded company that reported fiscal year 2025 financial results in a 10-K filing dated March 25, 2026. The company generated $653.8 million in revenue but incurred a net loss of $5.9 million for the year ending January 31, 2026. Liquidity metrics indicate a current ratio of 1.24 and a cash ratio of 0.47, reflecting moderate short-term financial flexibility. Recent quarterly news reports describe a pattern of narrowing losses year over year, driven in part by same-store sales growth and margin improvements, although revenue declines and operational challenges have also been reported. Economic challenges have been cited as impacting performance.

Health In Tech, Inc. is an AI-powered insurance technology platform company that offers a health insurance marketplace focused on self-funded benefits plans and stop loss insurance. The company leverages AI and machine learning to streamline underwriting, quoting, and sales processes, significantly reducing the time and complexity traditionally associated with these activities. HIT's platform serves insurance companies, licensed brokers, MGUs, and TPAs, providing customizable health benefits plans and network services. The company operates through three subsidiaries: Stone Mountain Risk (SMR), International Captive Exchange (ICE), and HI Card LLC, each contributing to the overall service offering. HIT's technology enables rapid generation of bindable quotes, often within two minutes, and provides a comprehensive healthcare management platform through HI Card. The company targets small to mid-sized employers, aiming to democratize access to affordable, flexible health insurance solutions. As of December 31, 2025, HIT had a broad client base across 40 states and reported significant revenue growth and profitability [S1].

Tron Inc. is a publicly traded company that has transformed from SRM Entertainment, Inc. into a blockchain-integrated treasury strategy company with a focus on TRX tokens, the native token of the TRON blockchain. Incorporated in Nevada in 2022, the company operates two main businesses: a toy and souvenir segment and a digital asset treasury segment. The toy and souvenir business designs and manufactures licensed merchandise for major theme parks worldwide, leveraging popular entertainment franchises. The digital asset treasury strategy involves accumulating and staking TRX tokens to generate yield through decentralized finance protocols. The company’s treasury wallet is self-managed and secured with regulated custodial services. Tron Inc. has engaged in significant capital raising activities to support its TRX token acquisitions and strategic initiatives. The company’s financials for 2025 reflect a net loss and negative earnings per share, with a strong current ratio indicating liquidity. The company faces risks related to token price volatility, regulatory uncertainties, and operational challenges in its merchandise business.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, particularly breast cancer and related conditions. Its lead product candidate, (Z)-endoxifen, is an oral selective estrogen receptor modulator/degrader in Phase 2 clinical development. The company is exploring multiple indications for (Z)-endoxifen, including breast cancer risk reduction, treatment of ER+/HER2- breast cancer, and rare diseases such as Duchenne Muscular Dystrophy and McCune-Albright Syndrome. (Z)-endoxifen is patented in the U.S. and internationally with protection through at least 2038. The company conducts several Phase 2 clinical trials evaluating efficacy and safety across different patient populations and treatment settings. Atossa has received FDA orphan drug designations for (Z)-endoxifen in DMD. Financially, the company reported a net loss of $34.8 million for 2025 and held $41.3 million in cash at year-end, with strong liquidity ratios. The company has no current revenue and depends on capital raises to fund operations. It also recently completed a reverse stock split to regain Nasdaq compliance.

Immix Biopharma, Inc. focuses on developing next-generation CAR-T cell therapies for serious diseases, with a lead candidate NXC-201 targeting relapsed/refractory AL Amyloidosis. The company’s N-GENIUS platform supports the design and manufacture of its cell therapies. NXC-201 is in Phase 1b/2 clinical trials in the U.S. and ex-U.S., with plans for a Biologics License Application submission following trial completion. The therapy has received FDA Breakthrough Therapy, RMAT, and Orphan Drug Designations, reflecting regulatory recognition of its potential. Immix has demonstrated positive clinical responses and a favorable safety profile in interim data. The company outsources manufacturing to contract organizations and has expanded clinical trial sites nationwide. Immix has raised capital through equity offerings and grants to support its development programs but continues to operate at a net loss with no approved products or revenues to date.

Axiom Intelligence Acquisition Corp 1 is a Cayman Islands exempted blank check company incorporated in January 2025. Its sole purpose is to identify and complete an initial business combination with one or more businesses or entities in any industry. The company completed its IPO in June 2025, raising $200 million, and simultaneously completed a private placement raising $6 million. The proceeds, except for working capital, are held in a trust account. The company has not generated operating revenues and has not yet entered into a definitive agreement for a business combination. The management team, led by experienced executives, is responsible for sourcing and completing the business combination, with a focus on European infrastructure sectors such as energy, digital, and transportation. The company must complete the business combination by June 20, 2027, or liquidate and return funds to shareholders. It may raise additional financing to complete the combination, which could dilute existing shareholders. The company maintains strong liquidity as of the latest fiscal year end.

Lionheart Holdings is a Cayman Islands exempted blank check company (SPAC) incorporated in February 2024. Its business objective is to identify and complete a business combination with one or more established businesses that have proven unit economics, capable management teams, and defensible market positions. The company completed its IPO in June 2024, raising $230 million, which is held in a trust account to fund the business combination. The company has no operating revenues or business operations prior to the business combination and must complete the transaction by June 20, 2026, or liquidate and return funds to shareholders. The management team leverages a broad network and proprietary deal flow to source potential targets. The company’s financial snapshot as of December 31, 2025, shows strong liquidity with a current ratio of 5.1 but no operating results. The company faces competition from other SPACs and investment groups in sourcing targets and has substantial doubt about its ability to continue as a going concern without completing a business combination or securing additional financing [S1][S2].

Finward Bancorp, incorporated in 1994, is the holding company for Peoples Bank, an Indiana-chartered commercial bank. The Bank operates 26 branches primarily serving Lake and Porter Counties in Northwest Indiana and Cook County, Illinois. Its core business involves attracting deposits and originating loans secured by residential and commercial real estate, construction, consumer, commercial business, and municipal loans. The Company also offers wealth management services including estate and retirement planning and trust services. The Bank's deposit accounts are insured by the FDIC, and the Company is regulated by the Federal Reserve Board, with the Bank also regulated by the FDIC and Indiana Department of Financial Institutions. The Company reports all operations as a single segment. As of December 31, 2025, total assets were approximately $2.0 billion, with loans receivable net of deferred fees and costs of $1.45 billion and deposits of $1.7 billion. The loan portfolio is diversified, with commercial real estate loans comprising the largest segment. The Company maintains a Board-approved appraisal policy for commercial loans and actively manages credit quality. Liquidity is supported by deposits, loan repayments, securities, and borrowing capacity from Federal Home Loan Bank and Federal Reserve facilities. The Company has a memorandum of understanding with regulators that includes restrictions on dividend payments without prior approval.

Stardust Power Inc. is a development-stage lithium refinery company formed in 2023, focused on constructing a battery-grade lithium carbonate (BGLC) refinery in Muskogee, Oklahoma. The refinery is designed to produce up to 50,000 metric tons per annum of BGLC, targeting the U.S. domestic market, including battery manufacturers, defense, and OEMs. The company employs a hub-and-spoke model sourcing lithium chloride feedstock from multiple brine suppliers across the Americas, aiming to reduce supply risk and cost. It has secured land for the facility, engaged engineering firms Hatch and Primero for project readiness and front-end engineering, and raised capital through public offerings and convertible debt. The company has not yet commenced production or sales and reported significant net losses and liquidity constraints as of the end of 2025. Stardust Power benefits from potential state and federal incentives and aims to contribute to U.S. energy independence and supply chain security in the lithium sector.

Central Bancompany, Inc. operates as a bank holding company with a focus on banking and financial services primarily in Missouri and surrounding markets. The company is regulated by the Federal Reserve and other federal and state agencies, requiring compliance with capital adequacy standards under Basel III and other regulatory frameworks. It provides a range of banking products and services, including loan origination, deposit accounts, and wealth management services. The company is engaged in modernizing its core banking technology infrastructure and has introduced new AI-enabled financial management tools. It faces competition from larger, better-capitalized financial institutions and is subject to risks related to geographic concentration, regulatory compliance, and technological change.

DT Cloud Star Acquisition Corp is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in late 2022. It raised gross proceeds of $69 million through an IPO in July 2024, with additional private placement proceeds. The company’s units trade on Nasdaq under the symbol DTSQU, with ordinary shares and rights trading separately under DTSQ and DTSQR. The company’s purpose is to identify and complete a business combination with a target business, leveraging its management team’s experience and network. The management team is led by CEO Sam Zheng Sun, who has a background in private equity and venture capital in Asia. The company’s acquisition strategy is broad, targeting businesses with strong market positions, recurring revenue, and growth potential, without industry or geographic restrictions. It entered into a business combination agreement with PrimeGen US, Inc., a biotech firm, in February 2026. The company’s financial position as of December 31, 2025, shows limited cash and a low current ratio, reflecting its SPAC status. The company has no operating history or revenues and will generate revenues only after consummating a business combination.